Discovery of APL-1030, a Novel, High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation

Uncontrolled complement activation contributes to multiple immune pathologies. Although synthetic compstatin derivatives targeting C3 and C3b are robust inhibitors of complement activation, their physicochemical and molecular properties may limit access to specific organs, development of bifunctiona...

Full description

Bibliographic Details
Main Authors: Joshua Garlich, Mathieu Cinier, Anne Chevrel, Anaëlle Perrocheau, David J. Eyerman, Mark Orme, Olivier Kitten, Lukas Scheibler
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Biomolecules
Subjects:
Online Access:https://www.mdpi.com/2218-273X/12/3/432